Amelia Dubovsky

Personal Statement

I am a Clinical Assistant Professor in the Department of Psychiatry and Behavioral Sciences at the University of Washington. I received my MD from New York University and completed my adult residency at the Harvard Massachusetts General Hospital/McLean Hospital program where I was chief resident. I then went on to complete a fellowship in psychosomatic medicine at the University of Washington. I am currently on faculty at Harborview Medical Center on the inpatient psychiatry consult service. I have a longstanding interest in the intersection between medicine and psychiatry, and am the author of numerous published articles on topics ranging from the neuropsychiatric effects of steroids to managing borderline personality disorder in the primary care setting. I have a particular interest in the use of electroconvulsive therapy, including in the treatment of catatonia. I am currently involved in research projects in conjunction with the division of nephrology and the neurosurgery department. In addition to my clinical and research interests, I am also an associate program director for the UW Adult Psychiatry Residency at Harborview Medical Center.

Garth Terry

Personal Statement

My research interests cover two main areas:

1) development and use of novel radioligands for positron emission tomography (PET) in CNS disorders

2) cannabinoid pharmacology, and cannabis use disorder and comorbid neuropsychiatric disorders

My VA Career Development Award (VA equivalent of an NIH K-award) focuses on the translational development of imaging neuroinflammation with PET following repetitive blast mild traumatic brain injury (mTBI). In collaboration with David Cook’s lab, imaging neuroinflammation in a mouse model of repetitive mTBI provides an opportunity to compare imaging outcomes directly with histopathology in brain tissue, which is not possible in humans. In collaboration with Elaine Peskind, imaging neuroinflammation in Veterans with mTBI and persistent post-concussive symptoms provides neuroanatomical specificity to ongoing neuroinflammation, which to date has been informed using cerebrospinal fluid and serum biomarkers. To accomplish this, my laboratory evaluates and develops established and novel PET radioligands for biomarkers of neuroinflammation. Additionally, I am interested in developing novel radioligands for druggable targets for which there are no current, suitable radioligands available. I have several ongoing collaborations with other investigators at UW and VA in which I provide support with PET imaging.

As a clinician and researcher, I am interested in how patients use cannabis for perceived therapeutic effect, and the risks and adverse outcomes resulting from substantial or chronic cannabis use. These clinical patterns can now be placed into context with a better understanding of the endocannabinoid system (ECS), which provide opportunity for more selective and safer therapeutic drug development. Due in part to the recentness of discovery of the ECS, one of my goals is to educate clinical providers on the preclinical and evidenced based research conducted to date on cannabis use and the ECS so they are better informed when discussing cannabis use with patients, and better prepared for understanding mechanisms of anticipated ECS-based medications currently under development. A second goal is to conduct research on cannabis use disorder and comorbid conditions, and identification of therapies that might better address a patient’s desired outcome from cannabis use, thereby reducing the likelihood of its associated risks.

Katherine Anne (Kate) Comtois

Personal Statement

My career goal is to give suicidal clients and their clinicians the best chance to succeed. I have been working in the area of health services, treatment development, and clinical trials research to prevent suicide for over 20 years. My graduate training was in community/clinical psychology and focused on achieving clinical ends through prevention and other systemic interventions in socio-culturally diverse populations. I have brought these perspectives into health services research.  I have developed or adapted interventions to improve care and clinician willingness to work with suicidal patients including Caring Contacts, Dialectical Behavior Therapy (DBT), Collaborative Assessment and Management of Suicidality (CAMS), and Preventing Addiction Related Suicide (PARS). I have developed an adaptation of DBT, Accepting the Challenges of Employment and Self-Sufficiency (DBT-ACES), a program to assist psychiatrically disabled individuals find and maintain living wage employment. My research has been funded by NIMH, NIDA, the Department of Defense, American Foundation for Suicide Prevention, the Department of Veteran Health Affairs, and the State of Washington.

I am the director of the Center for Suicide Prevention and Recovery (CSPAR) whose mission is to promote the recovery of suicidal individuals and the effectiveness and well-being the clinicians and families who care for them by conducting rigorous and ecologically valid research, developing innovative interventions, improving policies, systems and environments of care, and providing expert training and consultation. CSPAR faculty and staff seek a deep understanding of the cultures and settings in which we work that leads to meaningful and effective interventions ready for implementation.

In addition to clinical research, I founded the Society for Implementation Research Collaboration (SIRC) and am the PI and Director of the Military Suicide Research Consortium Dissemination and Implementation core.  These organizations focus on disseminating and implementing innovative, evidence-based interventions in the systems that need them. Beyond my research, I directed the Harborview Dialectical Behavior Therapy program at Harborview Medical Center 1996-2019, co-lead the UW DBT Training Program and have a long history of training and mentoring junior faculty, fellows, psychiatry residents, pre-doctoral psychology interns, undergraduate students, and post-baccalaureate trainees. I provide psychotherapy and consultation at the UWMC Outpatient Psychiatry Clinic.

Heidi Combs

Personal Statement

​Early in my training it became clear that intense pathology transfixed me so inpatient psychiatry was a natural fit. My specific area of expertise within psychiatry is care of the acutely ill hospitalized psychiatric patient. I have also developed clinical expertise in the diagnosis and management of Catatonia. In addition to clinical care, education is another area of interest. I love to teach and it has been the focus of my career. I am intimately involved in the education of psychiatry residents and am a founding faculty member of the Clinician-Teacher Pathway for our residency program. In addition to teaching medical students and residents, I regularly educate primary care providers on detection and treatment of psychiatric illnesses in primary settings. I assumed the role of Vice Chair of Education in 2020 and in that role I oversee all educational efforts for our department.

Erik S. Carlson

Personal Statement

I am a basic neuroscientist, a board-certified practicing psychiatrist, and an Assistant Professor of Psychiatry and Behavioral Sciences at the University of Washington Medical School. The goal of my research is to investigate the neural circuitry of cognitive, emotional and memory processing, particularly as it relates to the cerebellum, and illnesses affecting cerebellum including cognitive disorders, PTSD, TBI and dementia through the implementation of techniques in mouse behavioral genetics. In my clinical practice, I primarily see veterans with PTSD, mild cognitive impairment, and various forms of dementia in an outpatient clinic at the VAMC Puget Sound Geriatric Research, Education, and Clinical Center (GRECC) in Seattle. I have over 15 years of experience in basic science research with most of that time dedicated to the use of mouse models of neuropsychiatric disorders.   Throughout my training prior to and during graduate school, I gained background in many contemporary molecular and biochemical lab techniques, such as molecular cloning, protein biochemistry, protein crystal production, fluorometric measurement of protein kinetics, in vivo NMR spectroscopy, gene targeting, microarray genomics, immunohistochemistry, and mammalian cell culture. I have a foundation in mouse genetics, neural development, and behavior which I developed in Michael Georgieff’s lab by investigating the role of iron in developing pyramidal neurons of the mouse hippocampus. During graduate training, I also received cross-training in child psychological development. In graduate school, I developed two mouse models of nonanemic neuron specific iron deficiency: 1) a conditional knockout of the Slc11a2 gene, encoding the iron transporter DMT-1 in forebrain neurons, including hippocampal pyramidal neurons, and 2) a transgenic mouse with a reversibly inducible dominant negative (nonfunctional) form of the transferrin receptor expressed only in hippocampal pyramidal neurons. I utilized and implemented different versions of the Morris Water Maze to study learning deficits in these mouse models of perinatal brain iron deficiency, a condition that is often a consequence of diabetes during pregnancy.   During my residency training, I expanded my knowledge of neuropsychiatric disorders by directly evaluating and treating patients with neuropsychiatric disorders including PTSD, schizophrenia, Alzheimer’s disease, autism, major depression, substance abuse disorders, and personality disorders. I learned numerous pharmacological, neuromodulatory, and psychotherapeutic interventions and participated in the internally funded Neuroscience Research Track. I then received a NIMH career development award (K08) mentored by Larry Zweifel, Ph.D. In that position, I investigated interactions between catecholamines and the cerebellum in decision making, emotional and cognitive processing. In the 5 years I was in Dr. Zweifel’s lab, I learned many additional new techniques including use of viral vectors, in vivo electrophysiology, and several operant- and threat-based behaviors, and moved forward in my goal of becoming a physician scientist isolating important circuits underlying etiology of specific domains of behavioral function. This work culminated in my receiving an RO1 independent investigator award, without any gap in funding.   My current research utilizes mouse behavior, in vivo electrophysiological recordings, gene targeting, viral vectors, translational profiling, chemo- and optogenetic tools, site-specific intracranial viral vector injection, and protein chemistry. I am now forging my path as an independent investigator, and my primary goal is to understand cerebellar circuits as they relate to psychiatric and neurodegenerative illnesses and utilize this knowledge to inform and improve current and novel psychiatric illnesses, primarily in cognitive and emotional domains. As such, I am pursuing a multidisciplinary approach combining genetic, electrophysiological, pharmacological, and behavioral techniques.  

Taylor Black

Personal Statement

I came to the UW to train in psychosomatic medicine and to work in a complex comorbid population as a clinician and a teacher. Most medical and surgical patients served at Harborview will have psychosocial needs; often these are as critical to their recovery and health as somatic health problems. Working across disciplines is challenging but also clinically valuable, intellectually stimulating, and exciting to our trainees when we can address care in a more integrated and holistic manner. I like to focus my academic work on defining what the needs of Harborview’s clinical population are, and how our busy psychiatric consultation services can be best utilized to promote the health of our patients and our institutions.

Dror Ben-Zeev

Personal Statement

I am a Professor in the Department of Psychiatry and Behavioral Sciences at the University of Washington and licensed Clinical Psychologist who specializes in development and evaluation of technology-based approaches in the study, assessment, treatment, and prevention of mental illness. This work includes development of illness self-management apps for people with schizophrenia, texting interventions, behavioral sensing/digital phenotyping, computational psychiatry/predictive modelling, applications of Natural Language Processing (NLP), and development of culturally-relevant digital mental health resources for communities in low-and-middle-income countries. My research has been supported by grants and awards from the National Institutes of Health (NIH), National Science Foundation (NSF), Center for Medicare and Medicaid Innovation (CMMI) Patient Centered Outcomes Research Institute (PCORI), SYNERGY Clinical and Translational Science Institute, Myrtlewood Foundation, and John Sloan Dickey Center for International Understanding.  I publish extensively in scientific journals and am a regular speaker at national and international scientific meetings including invited presentations at the White House and National Institute of Mental Health Director’s Innovation Speaker series. I have written editorials and commentaries on the use of technology-based interventions for Psychiatric Services, the BMJ, and the New York Times, and my research has been covered by Public Radio, Nature, Wired Magazine, Slate, and The Economist. I served on the Editorial Board of Schizophrenia Bulletin and am the Inaugural Editor of the “Technology in Mental Health” Column for Psychiatric Services (APA journal).